Our expertise spans across many therapeutic areas, including ophthalmology, where Calvert enjoys a 30-year heritage and is highly regarded in the marketplace. Calvert’s specialized techniques and qualified management team set the foundation for the commercial success of numerous ocular therapeutics that remain on the market today.
Calvert Labs has performed safety assessments of test articles administered via numerous ocular routes for over thirty years. Topical administration has been performed with a variety of formulations.
Routes of administration include, but are not limited to:
Topical Study durations have ranged from single dose acute studies to studies of six- and nine-months duration. Additionally, pharmacokinetic studies have been performed via these routes in multiple species. The studies performed by Calvert Labs have supported numerous global regulatory submissions.
Calvert has enjoyed a 20-plus year partnership with Cornell University ophthalmologist, Thomas J. Kern, DVM, DACVO. Dr. Kern helped develop various techniques at Calvert and provides ophthalmology support based on study protocol. Dr. Kern is a well-known and highly regarded veterinarian in the field of veterinary ophthalmology.
Since 2001, Calvert has worked closely with Cornell University physiologist, Ellis R. Loew, PhD. Dr. Loew is a highly respected electrophysiologist who performs ERGs on study animals and interprets the data. The electroretinogram (ERG) is a mass electrical response of the retina produced in reaction to a light stimulus. The technique is a valuable tool designed to interpret changes in retinal function.
Typical ophthalmologic endpoints are listed below:
Typical ophthalmologic endpoints include the following:
Calvert Labs has a history of partnering with clients to successfully develop unique/novel techniques and procedures in the field of ocular research. Through our high levels of expertise, commitment to the development of cutting edge science and extended network of experts in preclinical ophthalmology, we remain capable and willing to partner with you to develop new methods and achieve your preclinical development goals.
For more information please contact:
Director, Project Management and Client Services
email@example.com | 570.585.2386